Entera Bio Seeks Approval for 13.9M Share Plan Increase and CEO/CFO/COO/R&D Top-up Grants
ENTX has more than doubled off its 52-week low of $0.91.
Summary
Entera Bio's preliminary proxy quantifies the equity compensation tied to its July $275M private placement: a 13.9M share plan increase and top-up grants to four executives totaling 8.4M options and 3.35M RSUs, with a shareholder vote set for November 24, 2026.
Key Events · Corporate Governance and Compliance · ENTX
-
2018 Plan Share Pool Increase
Proposal One seeks approval to increase the 2018 Equity Incentive Plan by 13,937,915 shares, bringing the unallocated pool to 10% of outstanding shares minus the top-up grants.
-
CEO Top-up Grant
Proposal Two grants CEO Miranda Toledano 3,351,790 options at $2.96 exercise price plus 3,351,790 RSUs, restoring her fully diluted ownership to 4.57%.
-
CFO, COO, and R&D Chief Grants
Proposals Three through Five grant CFO Dana Yaacov-Garbeli 1,595,260 options, COO Hillel Galitzer 1,950,925 options, and R&D Chief Gregory Burshtein 1,540,754 options, all at $2.96, restoring ownership to 1.09%, 1.33%, and 1.05% respectively.
-
Post-Termination Exercise Extension
Proposal Eight extends the post-termination option exercise period for officers and directors from 3 months to 5 years, applying retroactively to existing options.
Analysis · ENTX · Life Sciences
This proxy statement puts hard numbers on the equity compensation package tied to Entera Bio's July $275M private placement. Shareholders are asked to approve a 13.9 million share increase to the 2018 Equity Incentive Plan and one-time grants to four named executives totaling 8.4 million options plus 3.35 million RSUs. The CEO's grant alone restores her fully diluted ownership to 4.57%, while the CFO, COO, and R&D chief receive grants restoring 1.09%, 1.33%, and 1.05% respectively. The exercise price of $2.96 sits above today's $2.81 stock price, meaning these options are currently out of the money. The special meeting is scheduled for November 24, 2026, with a record date of October 1, 2026.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENTX was trading at $2.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $488.5M. The 52-week trading range was $0.91 to $4.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.